Aktienanalyse zu Picard Medical Inc (PMI)PMIPicard Medical Inc

Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber. It operates in the Healthcare sector.

Picard Medical Inc (PMI) appears to be a good buy right now due to its recent revenue growth of 39% in Q2 2026, reaching approximately $3.0 million, and a notable improvement in gross margin to 20.9%. However, the main risk is the ongoing net loss of approximately $5.7 million for the same quarter, which indicates that while the company is improving, it still faces significant financial challenges.